CRO and Vendor Oversight in Clinical Trials
ICH E6(R3) raises the governance bar for CRO and vendor oversight in clinical trials. Here's what sponsors must build into outsourcing relationships to protect trial quality and timelines.
Articles, expert interviews, and insights from life sciences leaders
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Ready to Deliver With Continuous Pharmaceutical Manufacturing
Continuous pharmaceutical manufacturing cuts production time by up to 90% and is now backed by ICH Q13. Here’s what manufacturing leaders need to know about the shift to CM.
Where Healthcare AI Investment Is Going — And Where It Isn't
The data is out: Two-thirds of AI healthcare startup investment went to just three domains. Insight into clinical leadership, gender inclusivity, and geographical access reveals a sector building for investability… not clinical need.
The Future for Decentralised Clinical Trials
Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.
Reimagine AI-driven Drug Discovery with Pharma Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
First Quarter 2026 State of Digital Health Funding
Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Digital Twins in Clinical Trials: Simulating Success Before Enrolment
Digital twins in clinical trials simulate patient outcomes to reduce risk and accelerate timelines. Learn how sponsors use them for predictive trial design.
How Pharmacy Innovation Is Changing Healthcare Delivery
Pharmacy is emerging as a critical but overlooked route to faster patient access. In this episode of Digital Pulse, Judit Mora explains how innovation, digital workflows, and pharmacy-led models can bypass traditional delays in healthcare delivery.
The Role of Regulatory Leadership in Healthcare
Regulatory leadership is no longer just compliance. In this episode of Chain Reaction, Dineshree Naiker explains why early regulatory strategy, supply chain governance, and value-based thinking are critical to improving patient access and healthcare outcomes.
Healthcare Supply Chains in Africa: Lessons from COVID-19
COVID-19 exposed major weaknesses in pharmaceutical supply chains. In this episode of Chain Reaction, Trisha Pillay and Émile Malan explore how AI, regulatory reform, and local manufacturing could strengthen healthcare resilience.
Phenotypic Drug Discovery: Beyond the Target
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
